WASHINGTON — Ninety-eight days may end up costing Johnson & Johnson. When Medicare this week announced the first 10 medicines that will be included in its brand-new drug price negotiation program, a J ...

DENVER (KDVR) — A Colorado board continues reviewing the cost of prescription drugs, and public feedback is wanted about the latest two under review. Cosentyx, which treats psoriasis, and Stelara, for ...

Medicare and its beneficiaries are paying significantly more for Stelara, Johnson & Johnson’s (NYSE:JNJ) popular biologic drug used to treat autoimmune diseases when obtained through pharmacies rather ...

Colorado’s Prescription Drug Affordability Review Board (PDAB) isn’t waiting for the Inflation Reduction Act (IRA) to lower prices on certain drugs starting in 2026. After the board previously voted ...

In May 2025, the FDA approved numerous biosimilars as interchangeable with Stelara ® (ustekinumab) and Humira ® (adalimumab), bringing the total number of Stelara ® interchangeables to four, plus an ...

Johnson & Johnson filed a lawsuit in a New Jersey federal court, against Samsung Bioepis for breaching its contract agreement with the company over the launch of a biosimilar to its autoimmune drug ...

Please provide your email address to receive an email when new articles are posted on . Imuldosa, an ustekinumab biosimilar, is approved for multiple inflammatory diseases, including Crohn’s disease ...

Dong-A-ST's Imuldosa (ustekinumab-srlf/DMB-3115), a biosimilar to Stelara, has won the Food and Drug Administration’s approval. “This FDA approval indicates ...

The FDA has approved a new biosimilar drug for inflammatory disease, based on the popular Stelara (ustekinumab). Biosimilar drugs are biologically similar, but not identical to existing biologics. The ...